Phenol Neurolysis for Spasticity: When Is a Nerve Block Considered?

Phenol neurolysis is a focused procedure used to reduce unwanted muscle overactivity by treating a selected peripheral nerve or motor branch. It is sometimes called a phenol nerve block, although its effect is different from the short-lived numbness produced by a routine local anaesthetic injection. The aim is not simply to lower a tone score. It is to make a specific activity, position or care task safer, easier or more comfortable.

Phenol is not the first or best option for every person with spasticity. It requires specialist assessment, precise nerve localisation and a clear plan for what will happen after the procedure. This guide explains when it may be considered, how clinicians select a target, what the procedure involves, how it compares with botulinum toxin and what benefits and risks should be discussed.

Key points

• Phenol neurolysis treats a selected nerve or motor branch rather than every muscle affected by spasticity.
• It may be useful when several problematic muscles share a nerve supply, when a relatively rapid effect is desirable or when botulinum toxin dose would otherwise be spread across many targets.
• Ultrasound and electrical stimulation can help identify the intended nerve and reduce exposure of nearby sensory, vascular and other structures.
• The effect may begin during the procedure and develop further over the following days. Duration varies substantially between people and targets.
• Reduced resistance is not automatically a functional improvement. Rehabilitation, positioning and task practice should be linked to a measurable goal.
• The evidence base is smaller and less standardised than that for botulinum toxin. Much of the published literature consists of retrospective series and specialist-centre experience.

What is phenol neurolysis?

Phenol is a chemical neurolytic agent. When a trained clinician places it around a selected peripheral nerve or motor branch, it alters nerve conduction and reduces the signal reaching the muscles supplied by that target. The procedure is therefore different from injecting a medicine directly into each muscle. One nerve may supply several muscles that contribute to the same pattern, such as the hip adductors drawing the legs together or the elbow flexors holding the arm bent.

The term “nerve block” can be confusing. A diagnostic block with local anaesthetic is intended to be temporary and may be used to test what happens when a nerve’s activity is reduced. Phenol neurolysis is intended to produce a longer effect. It is not permanent in every case, because peripheral nerves can recover or reinnervate over time, but recovery is variable and cannot be predicted precisely for an individual.

Phenol does not repair the brain or spinal cord injury that caused the upper motor neurone syndrome. It also does not remove weakness, poor selective control, sensory loss, pain, balance problems or a fixed contracture. This is why lowering muscle overactivity can be helpful for one person yet reduce useful support or stability for another.

When may phenol neurolysis be considered?

A specialist may consider phenol when focal or regional muscle overactivity interferes with a goal that matters to the person. Possible goals include opening the legs enough for hygiene, reducing painful spasms, improving sitting or positioning, making a splint easier to tolerate, reducing toe clawing, improving foot placement or allowing more effective practice in therapy. In some situations it may also help simplify daily care for family members or paid caregivers.

Phenol can be attractive when a group of overactive muscles shares a readily accessible motor nerve. Commonly described targets include motor branches serving the hip adductors, elbow flexors, wrist or finger flexors, and selected calf or foot muscles. The exact target is an anatomical and clinical decision. Treating a nerve that carries important sensation may increase the risk of altered sensation or neuropathic pain, so clinicians often prefer predominantly motor branches where possible.

It may also be considered when the required pattern would use a large proportion of the available botulinum toxin dose, when a quicker onset would be useful, or as part of a combined strategy in which phenol is used for one nerve distribution and botulinum toxin is reserved for other muscles. Combination treatment does not mean that more treatment is always better. Each target should have a reason and an outcome that can be reviewed.

Phenol is generally less useful when the apparent stiffness is mainly a fixed shortening, joint deformity or pain response rather than dynamic muscle overactivity. It may also be inappropriate when the functional consequence is uncertain or when the person relies on the overactivity for standing, transfers or walking. Availability and clinical practice differ between countries and services.

Assessment before treatment

The assessment starts with the person’s priorities. A goal such as “reduce tone” is too broad. A stronger goal might be “separate the knees enough for skin care without pain,” “place the heel more reliably during transfers,” or “reduce the number of night-time spasms that wake me.” The team can then decide whether the proposed nerve contributes to that problem and how success will be measured.

Examination usually includes passive range, the speed-dependent response to stretch, active movement, strength, selective motor control, sensation, pain, skin condition and the way the limb behaves during a real task. Standardised scales can support documentation, but they do not replace functional assessment. Our guide to measuring spasticity explains why the Modified Ashworth Scale alone cannot identify the best treatment.

The clinician also considers what could be lost. Hip adductor activity may be troublesome for hygiene but may contribute to stability during standing. Calf activity may cause an equinovarus posture yet also help a weak leg accept weight. Elbow flexor tone may interfere with dressing but help someone hold an object against the body. A careful assessment tries to separate unwanted activity from activity that remains functionally useful.

In selected cases, a temporary local anaesthetic block may be offered before neurolysis. This can provide a short window in which the person and team observe changes in range, comfort, transfers, walking or care. It is not a perfect prediction of phenol’s longer effect, and it is not required in every service, but it can be valuable when the balance between benefit and weakness is uncertain.

The team should review medicines, allergies, infection near the injection site, bleeding risk, pregnancy where relevant, previous reactions and other medical conditions. The individual service decides which precautions or medication changes are necessary. Anticoagulants or antiplatelet medicines should never be stopped without instructions from the prescriber and treating clinician.

What happens during the procedure?

Phenol neurolysis is normally performed by a clinician trained in peripheral nerve anatomy and spasticity management. The person is positioned so that the target can be reached safely and the limb is supported. The skin is cleaned, and local comfort measures may be used according to the target and the person’s needs.

Modern practice often combines ultrasound with electrical stimulation. Ultrasound shows the nerve and nearby tissues in real time. Electrical stimulation helps confirm that the selected structure activates the intended muscles. These tools do not remove all risk, but they improve localisation and may allow smaller, more targeted injections. Published specialist-centre series describe the combined approach for both predominantly motor nerves and carefully selected mixed nerves.

The clinician advances the needle under guidance, confirms the target and administers phenol according to the local protocol. The team may reassess the limb during or shortly after the procedure. The whole visit can take longer than the injection itself because positioning, mapping, confirmation and observation are important parts of safe treatment.

A person may feel pressure, a brief sting, muscle twitching during stimulation or soreness afterwards. The exact experience depends on the nerve, the volume treated, sensitivity and the comfort method used. Anyone worried about pain, communication difficulties or previous traumatic medical experiences should discuss this before the procedure so that the plan can be adapted.

How quickly does it work and how long can it last?

Phenol may produce an immediate reduction in nerve-driven muscle activity. A small retrospective study of people with elbow flexor spasticity found that part of the effect was visible immediately and that the measured effect continued to develop, appearing to peak at about one week. That finding is useful for planning, but it came from a small group and should not be treated as a timetable that applies to everyone.

Duration is variable. Effects may last for months, but the target nerve, technique, underlying condition, degree of recovery and individual nerve regeneration all matter. A longer effect is not automatically better. The relevant question is whether the benefit remains useful and whether excessive weakness, sensory symptoms or new movement problems appear.

Assessment should therefore continue after the procedure. An early review may focus on pain, unexpected weakness and the immediate care plan. Later reviews examine whether the agreed functional goal was achieved and whether the effect is stable, fading or exposing another problem such as fixed shortening or poor motor control.

Phenol neurolysis and botulinum toxin: how do they differ?

Both treatments can reduce focal muscle overactivity, but they act differently. Botulinum toxin is injected into selected muscles and reduces release of acetylcholine at the neuromuscular junction. Phenol is placed around a selected nerve or motor branch and affects conduction to the group of muscles it supplies. The choice is not simply between a “stronger” and a “weaker” treatment.

Phenol may have a rapid onset, can cover several muscles through one nerve target and is not limited by the same total-unit ceiling used for botulinum toxin. It can therefore help when a large pattern must be addressed or when toxin is better reserved for muscles that cannot be reached through a suitable motor branch. It may also be less expensive in some health systems.

Botulinum toxin offers muscle-by-muscle selection and has a larger modern evidence base for many spasticity patterns. Its effect is temporary and usually predictable enough to support planned review cycles. Phenol requires detailed nerve localisation and carries particular concern about pain or dysesthesia when sensory fibres are affected. In practice, specialists may use either treatment, combine them, or decide that neither is appropriate.

Shared decision-making should include the target, expected benefit, uncertainty, availability, previous response, rehabilitation plan and the person’s preference. Our overview of spasticity treatment options places focal procedures alongside rehabilitation, oral medicines, intrathecal treatment and surgery.

Risks, side effects and limitations

Common short-term effects can include pain at the injection site, tenderness, bruising and a sense that the limb feels different. Weakness is partly intended when an overactive motor pathway is treated, but too much weakness can impair transfers, standing, walking, reaching or grasping. A change that looks favourable during passive examination may therefore be unhelpful in real life.

Potential complications include altered sensation, dysesthesia or neuropathic pain, swelling, bleeding, infection, injury to nearby structures and unintended spread to other nerve fibres. Tissue irritation or damage is possible if phenol is not precisely placed. Serious systemic complications are uncommon in specialist practice but are part of the reason dosing, target selection and monitoring require expertise.

Evidence about safety and benefit is encouraging but limited. Retrospective reports from specialist centres describe successful treatment of hundreds of nerves with relatively few documented adverse events, including studies in stroke, brain injury and spinal cord injury. These studies do not provide the same certainty as large randomised trials. They may also miss symptoms not recorded in the chart or outcomes important to patients.

Phenol should not be presented as a guaranteed way to improve function. It can reduce a neural component of resistance, but the person may still have weakness, contracture, poor coordination, pain or limited endurance. The most responsible plan defines what success would look like and what the team will do if the expected benefit does not occur.

Rehabilitation after phenol neurolysis

Neurolysis creates an opportunity; it does not replace rehabilitation. When resistance decreases, the person may need to learn how to use the available range in daily tasks. A programme may include positioning, active movement, strengthening, balance work, walking practice, hygiene routines, caregiver training or review of seating and transfers.

The timing and intensity depend on the goal. If the aim is easier hand care, occupational therapy may focus on safe opening, skin inspection and practical washing methods. If the aim is improved foot placement, physiotherapy may assess gait again and decide whether an orthosis, footwear change or walking aid should be adjusted. If the goal is comfort, success may mean fewer painful spasms rather than more active movement.

Because the effect can evolve over several days, equipment and exercise plans may need review rather than an automatic return to the previous routine. A splint that fitted before treatment may exert pressure in a different place afterwards. Strengthening should target meaningful activity without assuming that every newly available degree of range can be controlled actively.

The plan should connect to clear treatment goals. Useful measures might include time needed for hygiene, number of spasms, pain during care, ease of transfers, walking speed, distance, falls, sleep interruption or the person’s rating of goal achievement. Tone scores can be recorded, but they are only part of the outcome.

Questions to ask the treating team

• Which nerve or motor branch are you proposing to treat, and which muscles does it supply?
• What specific problem are we trying to change?
• Could the current muscle activity be helping me stand, transfer, walk or hold an object?
• Would a temporary diagnostic block add useful information?
• Will ultrasound and electrical stimulation be used for localisation?
• What changes should I expect immediately, after one week and over the following months?
• What sensory symptoms, pain or weakness should prompt an urgent call?
• How will rehabilitation, equipment and follow-up be adjusted after the procedure?
• Why is phenol preferred over botulinum toxin, or why are both being combined?

When should you seek help after the procedure?

Follow the instructions provided by the treating service. Contact the clinical team promptly if pain is severe or worsening, weakness is much greater than expected, numbness or burning pain persists, swelling increases, the limb becomes cold or changes colour, or there are signs of infection such as spreading redness, discharge or fever. Seek urgent medical help for breathing difficulty, collapse, chest symptoms or another severe reaction.

A sudden change in spasticity before or after a procedure may also reflect infection, pain, bladder or bowel problems, skin injury, medication changes or another medical issue. Treating the nerve does not replace looking for these triggers.

Frequently asked questions

Is phenol neurolysis permanent?

Not necessarily. The effect can last for months, but nerves may recover or reinnervate and the clinical effect may fade. Duration varies, and no clinician can promise an exact period for an individual.

Can phenol neurolysis be repeated?

Repeat treatment may be considered after reassessment, but it is not automatic. The team reviews the previous benefit, adverse effects, current anatomy, functional goals and other options.

Can it improve walking?

It may help when a clearly identified nerve-driven pattern is limiting foot placement, knee control or leg separation. Walking also depends on strength, selective control, sensation, balance, range and confidence, so reducing tone alone may not improve gait and can sometimes reduce useful stability.

Is phenol the same as alcohol neurolysis?

Both are chemical neurolytic approaches, but they are different agents with different handling and local protocols. The appropriate agent and technique are specialist decisions.

Continue reading

Learn more about botulinum toxin injections, rehabilitation for spasticity, clinical and functional assessment, and the difference between spasticity and contracture.

Medical disclaimer: This page is provided as a public information service. It is not a substitute for personal medical advice, diagnosis or treatment from a qualified professional. Do not start, stop or change treatment on the basis of this page. In an emergency, contact local emergency services.

Last updated: 22 September 2026. The article reflects current clinical guidance and peer-reviewed evidence but is not presented as having undergone medical review.